Why the study?
Does single-dose combination antihypertension therapy improve blood pressure control and compliance in patients with hypertension compared to monotherapy?
Does single-dose combination antihypertension therapy improve blood pressure control and compliance in patients with hypertension compared to monotherapy?
Single-dose combination antihypertensive therapy is an important strategy to improve blood pressure control, minimize side effects, and enhance patient compliance compared to monotherapy.
Answers are grounded in this paper and cite their sources.
Reinforces consideration of combination strategies in hypertension; leaves open whether single-pill regimens improve adherence and outcomes versus monotherapy.
The recommendation for first-line therapy for hypertension remains a beta blocker or diuretic given in a low dosage. A target blood pressure of less than 140/90 mm Hg is achieved in about 50 percent of patients treated with monotherapy; two or more agents from different pharmacological classes are often needed to achieve adequate blood pressure control. Single-dose combination antihypertension therapyis an important option that combines efficacy of blood pressure reduction and a low side effect profilewith convenient once-daily dosing to enhance compliance. Combination antihypertensives include combined agents from the following pharmacological classes: diuretics and potassium-sparing diuretics,beta blockers and diuretics, angiotensin-converting enzyme (ACE) inhibitors and diuretics, angiotensin-II antagonists and diuretics and calcium channel blockers and ACE inhibitors.
No takes yet. Share an insight, caveat, or question.
Pattan et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: